Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8452476 | Experimental Hematology | 2018 | 34 Pages |
Abstract
There is a desperate need for new and effective therapeutic approaches to acute myeloid leukemia (AML) in both children and adults. Epigenetic aberrations are common in adult AML, and many novel epigenetic compounds that may improve patient outcomes are in clinical development. Mutations in epigenetic regulators occur less frequently in AML in children than in adults. Investigating the potential benefits of epigenetic therapy in pediatric AML is an important issue and is discussed in this review.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ashley A. Newcombe, Brenda E.S. Gibson, Karen Keeshan,